Subtopic Deep Dive

← Proteoglycans and glycosaminoglycans research

Proteoglycans in Angiogenesis Regulation
Research Guide

What is Proteoglycans in Angiogenesis Regulation?

Proteoglycans regulate angiogenesis by sequestering growth factors like VEGF and FGF through heparan sulfate chains, modulating endothelial cell sprouting and vessel formation.

Heparan sulfate proteoglycans such as syndecans and perlecan bind VEGF-A and FGFs in the extracellular matrix, controlling their spatiotemporal availability (Ruhrberg et al., 2002; Sarrazin et al., 2011). Knockout models reveal their angiostatic roles by inhibiting endothelial migration. Over 10 key papers from 1997-2018 explore these interactions, with Lu et al. (2012) cited 2932 times.

Curated Papers

Key Challenges

Why It Matters

Proteoglycans balance angiogenic switches in cancer progression, where ECM remodeling by proteoglycans promotes tumor vascularization (Lu et al., 2012). In ischemic therapies, their modulation enhances vessel growth via FGF signaling (Powers et al., 2000; Presta et al., 2005). CD44-hyaluronan interactions further regulate inflammation-driven angiogenesis in tumors (Misra et al., 2015). Therapeutic targeting of heparan sulfate proteoglycans sequesters VEGF to inhibit pathological angiogenesis (Ruhrberg et al., 2002).

Key Research Challenges

Spatial Growth Factor Gradients

Proteoglycans create localized VEGF-A gradients for vessel branching, but modeling these dynamics remains difficult (Ruhrberg et al., 2002). Knockout studies show disrupted morphogenesis, yet in vivo quantification challenges persist. Sarrazin et al. (2011) highlight variable ligand binding affinities complicating predictions.

Proteoglycan-FGF Interactions

Heparan sulfate chains on proteoglycans bind FGFs to regulate receptor signaling in angiogenesis (Presta et al., 2005; Powers et al., 2000). Dissecting specific chain structures versus core proteins requires advanced glycan analysis. Bikfalvi et al. (1997) note context-dependent roles in development.

ECM Remodeling in Cancer

Proteoglycans in tumor ECM dynamically alter stiffness and growth factor release, fueling angiogenesis (Lu et al., 2012). Heterogeneity among cancer-associated fibroblasts complicates targeting (Öhlund et al., 2014). CD44-mediated hyaluronan binding adds layers to inflammatory angiogenesis (Misra et al., 2015).

Essential Papers

The extracellular matrix: A dynamic niche in cancer progression

Pengfei Lu, Valerie M. Weaver, Zena Werb · 2012 · The Journal of Cell Biology · 2.9K citations

The local microenvironment, or niche, of a cancer cell plays important roles in cancer development. A major component of the niche is the extracellular matrix (ECM), a complex network of macromolec...

Heparan Sulfate Proteoglycans

Sandrine Sarrazin, William C. Lamanna, Jeffrey D. Esko · 2011 · Cold Spring Harbor Perspectives in Biology · 1.4K citations

Heparan sulfate proteoglycans are found at the cell surface and in the extracellular matrix, where they interact with a plethora of ligands. Over the last decade, new insights have emerged regardin...

The biology and role of CD44 in cancer progression: therapeutic implications

Chen Chen, Shujie Zhao, Anand B. Karnad et al. · 2018 · Journal of Hematology & Oncology · 1.4K citations

Fibroblast growth factors, their receptors and signaling.

Ciaran Powers, Sandra W. McLeskey, Anton Wellstein · 2000 · Endocrine Related Cancer · 1.3K citations

Fibroblast growth factors (FGFs) are small polypeptide growth factors, all of whom share in common certain structural characteristics, and most of whom bind heparin avidly. Many FGFs contain signal...

Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis

Marco Presta, Patrizia Dell’Era, Stefania Mitola et al. · 2005 · Cytokine & Growth Factor Reviews · 1.2K citations

Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis

Christiana Ruhrberg, Holger Gerhardt, Matt Golding et al. · 2002 · Genes & Development · 909 citations

Branching morphogenesis in the mammalian lung and Drosophila trachea relies on the precise localization of secreted modulators of epithelial growth to select branch sites and direct branch elongati...

Biological Roles of Fibroblast Growth Factor-2*

Andréas Bikfalvi, Sharon Klein, Giuseppe Pintucci et al. · 1997 · Endocrine Reviews · 882 citations

I. Introduction II. Structure of FGF-2 III. Mechanisms of Action of FGF-2: Extra- and Intracellular Signaling A. Exogenous 18-kDa FGF-2 B. Endogenous 18-kDa FGF-2 and HMW FGF-2 IV. Release of FGF-2...

Reading Guide

Foundational Papers

Start with Sarrazin et al. (2011) for heparan sulfate proteoglycan mechanisms and Ruhrberg et al. (2002) for VEGF gradient control, as they establish core binding and spatial roles cited in later works.

Recent Advances

Study Lu et al. (2012) for ECM-cancer dynamics and Misra et al. (2015) for CD44-hyaluronan in inflammation-driven angiogenesis.

Core Methods

Key techniques include knockout mice for sprouting assays (Ruhrberg et al., 2002), glycan binding studies (Sarrazin et al., 2011), and signaling pathway analysis in FGF systems (Presta et al., 2005).

How PapersFlow Helps You Research Proteoglycans in Angiogenesis Regulation

Discover & Search

Research Agent uses searchPapers and exaSearch to find papers on 'perlecan VEGF sequestration angiogenesis', pulling Ruhrberg et al. (2002) with 909 citations. citationGraph reveals connections from Sarrazin et al. (2011) to Presta et al. (2005), while findSimilarPapers expands to FGF-proteoglycan clusters.

Analyze & Verify

Analysis Agent employs readPaperContent on Lu et al. (2012) to extract ECM-angiogenesis mechanisms, then verifyResponse with CoVe checks claims against Sarrazin et al. (2011). runPythonAnalysis processes citation networks or quantifies heparan sulfate binding data from abstracts, graded by GRADE for evidence strength in knockout models.

Synthesize & Write

Synthesis Agent detects gaps in FGF gradient modeling post-Ruhrberg et al. (2002), flagging contradictions in CD44 roles (Misra et al., 2015). Writing Agent uses latexEditText for reviews, latexSyncCitations to link Presta et al. (2005), and exportMermaid for signaling pathway diagrams.

Use Cases

"Analyze heparan sulfate binding affinities in proteoglycan-VEGF interactions from recent papers"

Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (NumPy parsing of affinity data from Sarrazin et al., 2011) → matplotlib plots of binding curves.

"Write LaTeX review on syndecan roles in tumor angiogenesis with citations"

Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations (Lu et al., 2012; Presta et al., 2005) → latexCompile → PDF with figure captions.

"Find code for simulating proteoglycan-FGF gradient models"

Research Agent → paperExtractUrls → Code Discovery → paperFindGithubRepo → githubRepoInspect → Python scripts for spatial VEGF simulations linked to Ruhrberg et al. (2002).

Automated Workflows

Deep Research workflow scans 50+ papers via searchPapers on 'proteoglycans angiogenesis FGF VEGF', generating structured reports with GRADE-scored summaries from Sarrazin et al. (2011). DeepScan applies 7-step analysis with CoVe verification on ECM-cancer links (Lu et al., 2012), checkpointing gradient models. Theorizer builds hypotheses on angiostatic peptide mimetics from Presta et al. (2005) interactions.

Try Doxa for Proteoglycans in Angiogenesis Regulation Research

Frequently Asked Questions

What defines proteoglycans' role in angiogenesis regulation?

Proteoglycans like syndecans and perlecan bind VEGF and FGF via heparan sulfate, sequestering them to control endothelial sprouting (Ruhrberg et al., 2002; Sarrazin et al., 2011).

What methods study these interactions?

Knockout models and peptide mimetics dissect roles, with binding assays quantifying heparan sulfate gradients (Presta et al., 2005; Powers et al., 2000).

What are key papers?

Lu et al. (2012, 2932 citations) on ECM in cancer; Sarrazin et al. (2011, 1442 citations) on heparan sulfate proteoglycans; Ruhrberg et al. (2002, 909 citations) on VEGF gradients.

What open problems exist?

Quantifying in vivo glycan chain specificity and tumor fibroblast heterogeneity challenge therapeutic targeting (Öhlund et al., 2014; Misra et al., 2015).